Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-response adapted maintenance therapy for follicular lymphoma
ACTRN12619001264178Phase 3Completed
- Sponsor
- University of Liverpool
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab and lenalidomide in follicular lymphoma (FL), sponsored by University of Liverpool. Started Mar 2019; status: completed.
02
Drugs
rituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12619001264178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001264178.